IOPIDINE 0.5% Rx
Generic Name and Formulations:
Apraclonidine (as HCl) 0.5%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for IOPIDINE 0.5%:
Short-term adjunctive therapy to reduce elevated IOP.
Remove contact lenses; may reinsert 15min after instillation. 1–2 drops into affected eye(s) 3 times daily. Allow at least 5mins between instillation of other oph drugs.
Clonidine allergy. Concomitant MAOIs.
Monitor visual fields. Severe uncontrolled cardiovascular disease, hypertension, coronary insufficiency. Recent myocardial infarction. Cerebrovascular disease. Raynaud's disease. Thromboangiitis obliterans. History of vasovagal attack. Discontinue if ocular allergic-like reactions occur. Renal or hepatic impairment: closely monitor cardiovascular parameters. Depression. May mask hypoglycemia. Pregnancy. Nursing mothers (1% soln: discontinue nursing temporarily for 1 day of use).
See Contraindications. May potentiate CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Caution with TCAs, β-blockers, antihypertensives, cardiac glycosides, others (eg, clonidine). Concomitant CV drugs: monitor HR, BP periodically.
Hyperemia, pruritus, dry mouth, itching, discomfort, tearing, dizziness, solmnolence, lid edema, blurred vision, foreign body sensation, dry eye, conjunctivitis, discharge, blanching; tachyphylaxis may develop after 1 month; also in post-laser surgery: upper lid elevation, inflammation, nasal decongestion, mydriasis, irregular HR.
Soln 0.5% (5mL, 10mL)—1; 1% (0.1mL)—2
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma